These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2543344)

  • 21. Helvecardins A and B, novel glycopeptide antibiotics. III. Biological properties.
    Takeuchi M; Katayama T; Inukai M
    J Antibiot (Tokyo); 1991 Mar; 44(3):278-81. PubMed ID: 2026552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
    Printsevskaya SS; Solovieva SE; Olsufyeva EN; Mirchink EP; Isakova EB; De Clercq E; Balzarini J; Preobrazhenskaya MN
    J Med Chem; 2005 Jun; 48(11):3885-90. PubMed ID: 15916441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycopeptide antibiotic analogs for selective inactivation and two-photon imaging of vancomycin-resistant strains.
    Ariyasu S; Too PC; Mu J; Goh CC; Ding Y; Tnay YL; Yeow EK; Yang L; Ng LG; Chiba S; Xing B
    Chem Commun (Camb); 2016 Mar; 52(25):4667-70. PubMed ID: 26953360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new type of chemical modification of glycopeptides antibiotics: aminomethylated derivatives of eremomycin and their antibacterial activity.
    Pavlov AY; Lazhko EI; Preobrazhenskaya MN
    J Antibiot (Tokyo); 1997 Jun; 50(6):509-13. PubMed ID: 9268008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.
    Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Isakova EB; Reznikova MI; Goldman RC; Branstrom AA; Baizman ER; Longley CB; Sztaricskai F; Batta G; Preobrazhenskaya MN
    J Med Chem; 2002 Mar; 45(6):1340-7. PubMed ID: 11882003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemical modification of glycopeptide antibiotics].
    Pavlov AIu; Preobrazhenskaia MN
    Bioorg Khim; 1998 Sep; 24(9):644-62. PubMed ID: 9813730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [On contemporary rational penicillin treatment].
    Welcker ER
    Z Arztl Fortbild (Jena); 1965 Dec; 59(23):1250-3. PubMed ID: 5178687
    [No Abstract]   [Full Text] [Related]  

  • 30. [Glycopeptide antibiotics resistance mechanism as the basis for novel derivatives development capable to overcome resistance].
    Trenin AS; Olsuf'eva EN
    Bioorg Khim; 1997 Nov; 23(11):851-67. PubMed ID: 9518425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against gram-positive cocci.
    Ravizzola G; Pirali F; Foresti I; Turano A
    Drugs Exp Clin Res; 1987; 13(4):225-9. PubMed ID: 2957187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The structure and mode of action of glycopeptide antibiotics of the vancomycin group.
    Barna JC; Williams DH
    Annu Rev Microbiol; 1984; 38():339-57. PubMed ID: 6388496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limitations of presently available glycopeptides in the treatment of Gram-positive infection.
    Ziglam HM; Finch RG
    Clin Microbiol Infect; 2001; 7 Suppl 4():53-65. PubMed ID: 11688535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycopeptides: Update on an old successful antibiotic class.
    Pace JL; Yang G
    Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Battle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies.
    Dhanda G; Sarkar P; Samaddar S; Haldar J
    J Med Chem; 2019 Apr; 62(7):3184-3205. PubMed ID: 30404451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemistry and biology of glycopeptides with antibiotic activity.
    Tan H; Guo H; Wang S; Kong Q; Li W; Zeng W
    Protein Pept Lett; 2014; 21(10):1031-47. PubMed ID: 24975667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LL-AV290, a new antibiotic. II. Antibacterial efficacy in mice and in vitro.
    Redin GS; Dornbush AC
    Antimicrob Agents Chemother (Bethesda); 1968; 8():246-8. PubMed ID: 5735367
    [No Abstract]   [Full Text] [Related]  

  • 38. [Cloxacillin-susceptible Staphylococcus aureus with high MIC to glycopeptides. Ever we use cloxacillin?].
    Morales-Cartagena A; Lalueza A; San Juan R; Aguado JM
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():25-9. PubMed ID: 26365730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo efficacy and pharmacological properties of a novel glycopeptide (YV4465) against vancomycin-intermediate Staphylococcus aureus.
    Yarlagadda V; Konai MM; Paramanandham K; Nimita VC; Shome BR; Haldar J
    Int J Antimicrob Agents; 2015 Oct; 46(4):446-50. PubMed ID: 26188396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity.
    Pavlov AY; Berdnikova TF; Olsufyeva EN; Miroshnikova OV; Filipposyanz ST; Preobrazhenskaya MN; Sottani C; Columbo L; Goldstein BP
    J Antibiot (Tokyo); 1996 Feb; 49(2):194-8. PubMed ID: 8621361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.